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A
CD● LV dysfunction with dilatation of the ventricle and
regional asynergy (either akinetic or dyskinetic).
When LV asynergy is severe and diffuse, SVR can be
performed only if regions remote from the scar have
some degree of contraction detectable at rest or under
inotropic stimulus (like dobutamine test).
● HF symptoms are the first indication for SVR, but also
patients presenting with ventricular arrhythmias
and/or angina who need surgical revascularization
represent an indication for SVR (if the previous con-
ditions are present) to avoid further dilatation.
● For patients who are asymptomatic despite postinfarc-
tion LV dysfunction, we suggest that serial echocar-
diographic studies be performed to detect the first
signs of deterioration (ie, LV progressive enlargement
or decline in EF).
The following are contraindications:
● Severe right ventricular dysfunction (biventricular di-
lated cardiomyopathy) (absolute).
● Severe pulmonary hypertension not associated with
MR (relative).
● Severe regional asynergy without LV dilatation (ab-
solute).
● Restrictive diastolic pattern associated with high func-
tional class and MR (absolute).
When patients have relative or absolute contraindications
r when cardiac dysfunction is severe and diffuse, we per-
orm a stress echo dobutamine test. If contractility im-
roves, we perform SVR; if it does not improve and other
ptions such as transplantation are available, heart trans-
lant should be done. However, in some elderly patients
hen full medical therapy and other devices fail to improve
linical status, SVR can be the only treatment option and
oth patients and surgeons should be aware of an increased
ortality risk.
onclusions
ur study is observational and not randomized. Collection
f data is not uniform, being prospective in a minority of our
opulation, which remains the largest reported until now.
he severity of HF was based on NYHA functional class,
hich has limitations; we did not estimate quality of life,
hich is critical in this kind of patient with severe HF. We
xpect the STICH trial to answer all these critical questions.
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iscussion
r Andrew S. Wechsler (Philadelphia, Pa). This and Vincent
or’s series comprise the two largest observational series from
ingle centers on this operative procedure, at least to my knowl-
dge. Your results in this very challenging group of patients are
xcellent. I have four questions for you.
First, when I read the manuscript I noted that you used patch
losure only in about 50% of the patients. Should I take away the
mplication that many of these ventricles were not severely dilated,
r perhaps that you did the SVR as an incidental procedure when
he primary operation was in fact coronary revascularization?
My second question, and I have asked Dr Dor this same
uestion on several occasions, is this. When I did the calculations
ased on your own data, although there was an important increase
n EF, I found little or no increase in stroke volume. Are you
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A
CDurprised that despite a reduction in end-diastolic volume, there is
o increase in stroke volume? Do you think this implies that the
rimary benefit of the procedure is, in fact, in reducing myocardial
xygen consumption at the same external work level, or is it
ossible that after the surgery there is, in fact, restricted filling of
he ventricles owing to a change in diastolic properties?
I noted that you indicated that pulmonary artery pressure
reater than 60 mm Hg was a warning sign to you and that you
ended not to operate on those patients, but I did not see within
our data any actual calculation of pulmonary artery pressure as a
ontinuous variable associated with enhanced mortality. Maybe
ou could comment on that.
Finally, in your analysis, MR and increased end-systolic vol-
me both turn out to be predictors of poor outcome and mortality.
id you analyze these as discrete variables, or is the MR just a
arker of a more severely dilated ventricle and not really different
rom ventricular size as a risk factor?
Dr Menicanti. Dr Wechsler, thank you very much for your
uestions, which are really crucial in this type of procedure. The
rst question concerns the type of closure that we have to employ.
he decision to use or not use the patch is determined by the anatomic
haracteristic of the ventricle. If the volume of the ventricle is not
oo big or the transitional zone is distal, the probability to close the
entricle without a patch is high. By contrast, if you have a very
ig ventricle or if you have calcification of the septum or if the
alls of the LV are thick, this condition normally implied the use
f a patch. I think that the patch is related to the real anatomic
ituation of the ventricle. That is an important tool in the decision-
aking to use a sizer. In effect, since we have started to use the
izer, the number of patches has increased.
Your second question is really more complicated. My idea, and
urely I can be wrong, is that there are two possibilities. First, in
ome patients we have seen, with magnetic resonance imaging,
ith echo, and with angiograms, that the basal portion presents an
ncreased contractility. Thus there is a hyperkinesia. When we
educe the volume, this portion goes to a normal contractility, and
onsequently the stroke volume does not change in this particular
ase. The other possibility is that there is a direct relationship
etween stroke volume and the preload. This relation is called the
ardiac functional relationship. The curve increases up to a certain
evel: at this point, increasing the preload does not increase the
troke volume, and this point represents the limit of the maximal
reload reserve. If we decrease the preload, decreasing the volume
f the LV cavity, the stroke volume does not change because we
re moving in the upper part of the curve. What has changed is the
reload reserve; the patient now has a preload reserve. This I think
s the reason why the patients do better, because finally they regain
reload reserve. In this situation we have improved mechanical
fficiency with reduced oxygen consumption for the same external
ork.
Pulmonary hypertension, as you rightly stated, is not consid-
red as a predictive factor in our analysis. This is determined by
he fact that we did not achieve statistical evidence, because for
his value in our database there are several missing data. Clinically,
e consider pulmonary hypertension a very important predictor of
omplication after the intervention, but unfortunately we were
nable to prove it statistically. We hope that by collecting data in d
40 The Journal of Thoracic and Cardiovascular Surgery ● Auguprospective way in the past 5 years we finally have the data to
emonstrate this aspect statistically.
According to MR and dimension, Marisa Di Donato in the
merican College of Cardiology meeting in 2003 demonstrated a
lear relationship between the degree of MR and ventricular end-
iastolic volume and shape. Particularly, there is a strict correla-
ion between the transverse diameter and MR. I think MR is the
ffect of a bigger ventricle, and particularly of a large ventricle that
resents an involvement of the inferolateral wall determined either
y an extension of an anterior infarction or by a second infarction
n this region. This is particularly true when we treat patients who
ave a double-sided myocardial infarction, an anterior and an
nferior. This type of patient, because the distance between the
apillary muscles is increased in a very important way, very
requently has MR. This group of patients is very difficult to treat
ecause the quality of the remote myocardium is poor.
Dr John V. Conte, Jr (Baltimore, Md). As one of the many
urgeons you have allowed to visit you in Milan and to watch you
perate, I want to thank you for sharing your wealth of experience.
know I have benefited from it greatly.
My question has to do with the role of ventricular restoration
nd transplantation in the treatment of end-stage heart disease.
here do you see transplantation in those patients who were in
lass III or class IV, the highest risk populations, who are poten-
ially candidates for each operation? Probably half of the patients
hat I operate on are candidates for either operation. When we
iscuss the risks and benefits and alternatives, it is hard sometimes
o provide a good black-and-white answer regarding what opera-
ion is appropriate. Can you give us any insight as to how you
ddress that?
Dr Menicanti. Thank you very much. You are perfectly right.
f we have a patient who has diastolic dysfunction, MR, NYHA
lass III or IV, and pulmonary hypertension, we know for sure that
ur mortality in this group of patients is high, 20% to 25%. It is
ery difficult to propose a surgical procedure like that to the
atient. There is no question that the heart transplant is the best
hoice. The problem is that the great majority of these patients are
t an age that is not suitable for heart transplant. The mean age of
ur group in the past 5 years is 65 years. Last year 300 transplants
ere performed in Italy—very few. If the patient is young, there is
o question that you have to send them to heart transplant. If the
atient is old with comorbidities, I think that this procedure is the
nly choice that we have.
Dr Robert A. E. Dion (Leiden, The Netherlands). We try to
ollow your example in Leiden, and last year we performed as
any as 50 SVRs according to Dor. I just have a short question
bout the sizing of the residual cavity in the LV. I hear that you
ecommend sometimes 50, sometimes 60 mL/m 2. I think it is a
ery important topic because it is probably a determining factor for
iastolic function. Could you elaborate on your thoughts about
hat? When are you using a smaller volume, when are you using a
igher volume, and why?
Dr Menicanti. That is a very nice question and not so easy to
nswer. From a very practical point of view, we use a small
olume (ie, 50 mL/m2) when the basal portion of the ventricle is
ormal, so that the transverse diameter is almost in the range of
ormality. When we have a more important dilatation or global






























































Menicanti et al Surgery for Acquired Cardiovascular Diseasery to keep the longitudinal diameter more or less double the
ransverse diameter, we use a bigger size, 60 or 65 mL/m2 some-
imes. The choice of a bigger balloon is determined by dilatation
f the basal portion.
Dr David H. Adams (New York, NY). Dr Menicanti, can you
ell us a little bit more about this mitral valve subgroup in the sense
f what percent had primary anterior infarction, how you dealt
ith that, did you see an increased mortality with replacement
ersus repair, and did you use annuloplasty or repair all of these
rom inside the ventricle?
Dr Menicanti. All patients that we are describing in this group
ad an anterior myocardial infarction. Now, 20% of the patients
ho are operated on are also operated on for a mitral plasty. I think
he mortality in this group of patients is higher because the exten-
ion of the infarction is really very important and because the basal
ortion in this group of patients is not normal. Sometimes there is
nother infarction in that portion, sometimes there is fibrosis
ecause this situation lasts for such a long time and the myocytes
an be transformed into a fibroblast. The fact that we have in-
reased mortality depends, in my opinion, and I can be wrong, on
he fact that in this group of patients the residual contractile
yocardium is not so good as in the other situation. We have 13%
ortality when the mitral valve is approached. In the past 2 years
his mortality has decreased, probably because we are just a little
etter, but it is around 10%. I think that is determined by the
uality of tissue that we have. We approach the mitral valve in the
reat majority of the cases (95%) through the ventricle. When the
pening of the ventricle is small and it is difficult to see the valve,
e approach through the left atrium, but normally the ventricle that
resents MR is a big one.
Dr Robert H. Jones (Durham, NC). I congratulate Dr Meni-
anti, Dr Di Donato, and the others at San Donato on a beautiful
bservational study, remarkable for including all of your patients d
The Journal of Thoracicnd well describing their outcomes into subgroups. One subgroup
ou did not mention was the 22 patients that during the past 3 years
ou did choose to randomize into the STICH trial, and you are
dding also to the other hypothesis comparing the value of CABG
dded to medicine in this cohort. Would you share with us, first of
ll, the differences that made you at equipoise in those 22 patients
ompared with the others? How did you deal with telling the
amilies and the referring physicians that, on one hand, you are
oing the standard operation but in another situation you are
illing to randomize? You have taught many of us how to do this
peration. We in North America, as we are facing the opportunity
o put together a network to do more randomized clinical studies,
eed to learn from our European colleagues, who enroll more
atients into the STICH trial than we have in North America, how
o deal with this latter problem. Could you share your insight,
lease?
Dr Menicanti. Thank you, Dr Jones. This is really a problem
or us, because we believe in this procedure. The idea to randomize
he patients is sometimes very, very difficult. But what we did is a
ery simple issue. We know that this procedure is absolutely
antastic when there is a good or a relatively good basal portion,
nd we know the surgical mortality is really very low. So these are
he patients whom I did not randomize. Those whom I randomized
ere the patients with globally dilated cardiomyopathy, as we have
een in the echo in the beginning of my presentation, in whom I
now that the mortality is increased and in whom I have some
oubt about the outcome in terms of life expectancy. I randomize
atients if I am not sure they are not good candidates. And I
xplain that to them. Normally, they are in a very bad functional
lass, all are in full medical therapy, and they understand that their
ife expectancy is not long. They understand that we are trying to
o something to help, and they accept being randomized.
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